Journal
PHYSICA MEDICA-EUROPEAN JOURNAL OF MEDICAL PHYSICS
Volume 44, Issue -, Pages 139-149Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.ejmp.2017.02.003
Keywords
Lung cancer; SBRT; Hypo-fractionation; MRI guidance; Adaptive radiotherapy
Funding
- Elekta AB
- Cancer Research UK [C33589/A19727, C33589/A19908]
- NIHR Biomedical Research Centre at The Royal Marsden
- Institute of Cancer Research
- Cancer Research UK [19727] Funding Source: researchfish
Ask authors/readers for more resources
Stereotactic body radiotherapy (SBRT) is rapidly becoming an alternative to surgery for the treatment of early-stage non-small cell lung cancer patients. Lung SBRT is administered in a hypo-fractionated, conformal manner, delivering high doses to the target. To avoid normal-tissue toxicity, it is crucial to limit the exposure of nearby healthy organs-at-risk (OAR). Current image-guided radiotherapy strategies for lung SBRT are mostly based on X-ray imaging modalities. Although still in its infancy, magnetic resonance imaging (MRI) guidance for lung SBRT is not exposure-limited and MRI promises to improve crucial soft-tissue contrast. Looking beyond anatomical imaging, functional MRI is expected to inform treatment decisions and adaptations in the future. This review summarises and discusses how MRI could be advantageous to the different links of the radiotherapy treatment chain for lung SBRT: diagnosis and staging, tumour and OAR delineation, treatment planning, and inter-or intrafractional motion management. Special emphasis is placed on a new generation of hybrid MRI treatment devices and their potential for real-time adaptive radiotherapy. (C) 2017 Associazione Italiana di Fisica Medica. Published by Elsevier Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available